Navigation Links
Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference

EAST BRUNSWICK, N.J., Sept. 13, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that John H. Johnson, Chief Executive Officer and President of Savient will present at the Sixth Annual JMP Securities Healthcare Conference on Wednesday, September 28, 2011 at 9:30 a.m. Eastern Time.  The conference will be held at the St. Regis hotel in New York City.

A live webcast of the presentation can be accessed through the investor relations section of the Company's website at  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy.  Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA.  MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.  For more information, please visit the Company's website at

SVNT - GContact:Mary Coleman

Carney Noensie Savient Pharmaceuticals, Inc.

Burns (732) 418-9300

(212) 213-0006

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
2. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
3. Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
4. Savient Pharmaceuticals Reports Second Quarter 2011 Financial Results
5. Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
6. Savient Pharmaceuticals Marketing Authorization Application for KRYSTEXXA® Accepted for Review by European Medicines Agency
7. Savient Pharmaceuticals Reports First Quarter 2011 Financial Results
8. Savient Pharmaceuticals Submits European Marketing Authorization Application for KRYSTEXXA®
9. Savient Pharmaceuticals Names Seasoned Pharma Exec Richard Crowley EVP Biopharmaceutical Operations
10. Savient Pharmaceuticals to Present Multiple Abstracts at The European League Against Rheumatism (EULAR) 2011 Annual Congress
11. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
(Date:6/23/2016)... June 23, 2016 The vast majority of ... dialysis facility.  Treatments are usually 3 times a week, ... visit, including travel time, equipment preparation and wait time. ... especially grueling for patients who are elderly and frail.  ... nursing and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
Breaking Medicine News(10 mins):